Huda Y. Zoghbi
At a glance: Huda Y. Zoghbi is Director at Regeneron Pharmaceuticals (REGN). Their latest SEC Form 4, filed Nov 5, 2026, reported a sale of $6.7M. On file: 0 purchase lines ($0) and 14 sale lines ($9.1M).
Disclosed holdings: about $1.6M of REGN stock: 1,703 shares reported on their latest Form 4 (filed Nov 5, 2026), valued at the Nov 19, 2026 close of $932.53. This counts only REGN shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
Director at Regeneron Pharmaceuticals, Inc. (REGN)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Huda Y. Zoghbi's InsiderPrint
14 trades from SEC Form 4 filings, 2026 to 2026, drawn as one fingerprint.
Reading this print: Almost only sells, trading about 14 times a year, typically $163K a trade; most sales are on a pre-planned 10b5-1 schedule; trades in the same month most years.
- Bump outward: a purchase (0)
- Dent inward: a sale (14)
- One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.
Insiders with a similar print
- Steven A. MarkelDirector · MKL · 99% match
- Harold H. ShlevinDirector · GALT · 99% match
- Octavio EspinozaCFO · LGND · 99% match
- Chad Michael WhalenEvp, Worldwide Sales · FFIV · 99% match
- Daniel Stanley PerottiCFO · PFSI · 99% match
Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Nov 5SEC | REGNRegeneron Pharmaceuticals, Inc. | Sell | 6,9392,203 held (−76%) | $970.42 | $6.7M | -3.9% |
| Nov 5SEC | REGNRegeneron Pharmaceuticals, Inc. | Sell | 5001,703 held (−23%) | $971.06 | $486K | -4.0% |
| Aug 12SEC | REGNRegeneron Pharmaceuticals, Inc. | Sell Plan | 8001,703 held (−32%) | $800.00 | $640K | +16.6% |
| Feb 23SEC | REGNRegeneron Pharmaceuticals, Inc. | Sell Plan | 493,292 held (−1%) | $774.68 | $38K | +20.4% |
| Feb 23SEC | REGNRegeneron Pharmaceuticals, Inc. | Sell Plan | 503,242 held (−2%) | $775.50 | $39K | +20.2% |
| Feb 23SEC | REGNRegeneron Pharmaceuticals, Inc. | Sell Plan | 533,189 held (−2%) | $778.47 | $41K | +19.8% |
| Feb 23SEC | REGNRegeneron Pharmaceuticals, Inc. | Sell Plan | 2082,981 held (−7%) | $779.55 | $162K | +19.6% |
| Feb 23SEC | REGNRegeneron Pharmaceuticals, Inc. | Sell Plan | 3312,650 held (−11%) | $780.45 | $258K | +19.5% |
| Feb 23SEC | REGNRegeneron Pharmaceuticals, Inc. | Sell Plan | 2092,441 held (−8%) | $781.28 | $163K | +19.4% |
| Feb 23SEC | REGNRegeneron Pharmaceuticals, Inc. | Sell Plan | 2982,143 held (−12%) | $782.10 | $233K | +19.2% |
| Feb 23SEC | REGNRegeneron Pharmaceuticals, Inc. | Sell Plan | 2201,923 held (−10%) | $783.29 | $172K | +19.1% |
| Feb 23SEC | REGNRegeneron Pharmaceuticals, Inc. | Sell Plan | 1601,763 held (−8%) | $784.45 | $126K | +18.9% |
| Feb 23SEC | REGNRegeneron Pharmaceuticals, Inc. | Sell Plan | 561,707 held (−3%) | $785.61 | $44K | +18.7% |
| Feb 23SEC | REGNRegeneron Pharmaceuticals, Inc. | Sell Plan | 41,703 held (−0%) | $790.00 | $3K | +18.0% |
- Sell
Director Huda Y Zoghbi sold $6.7M of REGN at $970.42 — cuts the stake by 76%.
- Sell
Director Huda Y Zoghbi sold $640K of REGN at $800.00 — cuts the stake by 32%; pre-scheduled 10b5-1 plan sale.
- Sell
Director Huda Y Zoghbi sold $38K of REGN at $774.68 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Huda Y Zoghbi sold $39K of REGN at $775.50 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Huda Y Zoghbi sold $41K of REGN at $778.47 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Huda Y Zoghbi sold $162K of REGN at $779.55 — pre-scheduled 10b5-1 plan sale.
Follow Huda Y. Zoghbi
Get one email when Huda Y. Zoghbi files a new purchase or sale. Free.
At most one email a day about Huda Y. Zoghbi, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.